Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04960709 |
|---|---|
| Brief Title: | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA) |
| First Submitted : | June 17, 2021 |
| First Submitted that Met QC Criteria : | July 2, 2021 |
| First Posted : | July 14, 2021 |
| Last Update Submitted that Met QC Criteria : | March 21, 2024 |
| Last Update Posted : | March 22, 2024 |